DAFTAR PUSTAKA

Abukhdeir, A. M. and Park, B. H. (2008) 'P21 and p27: roles in carcinogenesis and drug resistance.', *Expert reviews in molecular medicine*. NIH Public Access, 10, p. e19. doi: 10.1017/S1462399408000744.

Babjuk, M. *et al.* (2017) 'EAU Guidelines on Bladder Cancer (TaT1 and CIS)', pp. 1–47.

Barabas, K. *et al.* (2008) 'Cisplatin : a review of toxicities and therapeutic applications', *Veterinary and Comparative Oncology*, 6(1), pp. 1–18.

Bellmunt, J. and Petrylak, D. P. (2012) 'New Therapeutic Challenges in Advanced Bladder Cancer', *YSONC*. Elsevier Inc., 39(5), pp. 598–607. doi: 10.1053/j.seminoncol.2012.08.007.

Besson, A., Dowdy, S. F. and Roberts, J. M. (2008) 'CDK Inhibitors: Cell Cycle Regulators and Beyond', *Developmental Cell*. doi: 10.1016/j.devcel.2008.01.013.

Burger, M. *et al.* (2012) 'Epidemiology and Risk Factors of Urothelial Bladder Cancer', *European Urology*. European Association of Urology, pp. 1–8. doi: 10.1016/j.eururo.2012.07.033.

Callus, B. A. and Vaux, D. L. (2007) 'Caspase inhibitors : viral , cellular and chemical', *Cell Death and Differentiation*, 14, pp. 73–78. doi: 10.1038/sj.cdd.4402034.

Costantini, C. and Millard, F. (2011) 'Update on Chemotherapy in the Treatment of Urothelial Carcinoma', *The Scientific World Journal*, 11, pp. 1981–1994. doi: 10.1100/2011/590175.

Dang, J. H. *et al.* (2017) 'Metformin in combination with cisplatin inhibits cell viability and induces apoptosis of human ovarian cancer cells by inactivating ERK 1/2', *Oncology Letters*, 14(6), pp. 7557–7564. doi: 10.3892/ol.2017.7176.

Dasari, S. and Tchounwou, P. B. (2015) 'Cisplatin in cancer therapy : molecular mechanisms of action', *Eur J Pharmacol*, pp. 364–378. doi: 10.1016/j.ejphar.2014.07.025.Cisplatin.

De, V., Hellman and Rossenberg (2011) *Platinum Analogs: cancer principles and practice of Oncology*. Lippincot Williams Wilkins.

Foretz, M. and Viollet, B. (2011) 'Hepatology Snapshot Regulation of hepatic metabolism by AMPK Hepatology Snapshot', *Journal of Hepatology*. European Association for the Study of the Liver, 54(4), pp. 827–829. doi: 10.1016/j.jhep.2010.09.014.

Graham, G. *et al.* (2011) 'Clinical Pharmacokinetics of Metformin Clinical Pharmacokinetics of Metformin', *Clin Pharmacokinet*, 50 (2)(February). doi: 10.2165/11534750-

000000000-00000.

Hall, M. C. *et al.* (2007) 'Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update', *American Urological Association Education and Research*, 178(December), pp. 2314–2330. doi: 10.1016/j.juro.2007.09.003.

Herr, H. W. *et al.* (2007) 'Defining Optimal Therapy for Muscle Invasive Bladder Cancer', 177(February), pp. 437–443. doi: 10.1016/j.juro.2006.09.027.

Hickling, D. R., Sun, T.-T. and Wu, X.-R. (2016) 'Anatomy and Physiology of the Urinary Tract: Relation to Host Defense and Microbial Infection', *Microbiol Spectr*, 3(4), pp. 1–29. doi: 10.1128/microbiolspec.UTI-0016-2012.Anatomy.

Hpa, N. G. *et al.* (2005) 'Metformin and reduced risk of cancer in diabetic patients', 330(JUNE), pp. 1304–1305. doi: 10.1136/bmj.38393.572188.EB.

Hu, J. *et al.* (2018) 'Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients', *Medicine*, 0(April).

Jeong, Y. K. *et al.* (2015) 'Metformin radiosensitizes p53-deficient colorectal cancer cells through induction of G2/M arrest and inhibition of DNA repair proteins', *PLoS ONE*, 10(11), pp. 1–15. doi: 10.1371/journal.pone.0143596.

Juffs, H. G., Moore, M. J. and Tannock, I. F. (2002) 'Chemotherapy for urothelial cancer The role of systemic chemotherapy in the management of muscle-invasive bladder cancer', 3(December), pp. 738–747.

Kumar, V., Abbas, A. K. and Aster, J. C. (2013) *Robbins Basic Pathology*. 9 ed. Saunders : Elsevier Inc.

Lee, J. O. *et al.* (2019) 'Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51', *Breast cancer research : BCR*. Breast Cancer Research, 21(1), p. 115. doi: 10.1186/s13058-019-1204-2.

Lesan, V. *et al.* (2014) 'Evaluation of antagonistic effects of metformin with cisplatin in gastric cancer cells', *International Journal of Hematology-Oncology and Stem Cell Research*, 8(3), pp. 12–19.

Maase, H. Von Der *et al.* (2005) 'Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin , With Methotrexate , Vinblastine , Doxorubicin , Plus Cisplatin in Patients With Bladder Cancer', *Journal of Clinical Oncology*, 23(21). doi: 10.1200/JCO.2005.07.757.

Moro, M. *et al.* (2018) 'Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Nsclc, Co-mutated Kras L K B', *Journal of Thoracic*

Oncology. Elsevier Inc, pp. 1–13. doi: 10.1016/j.jtho.2018.07.102.

Muller, J. *et al.* (2005) 'Drug specificity and intestinal membrane localization of human organic cation transporters (OCT)', *Biochemical Pharmacology*, 70, pp. 1851–1860. doi: 10.1016/j.bcp.2005.09.011.

Nies, A. T. *et al.* (2011) 'Proton Pump Inhibitors Inhibit Metformin Uptake by Organic Cation Transporters (OCTs)', *PloS one*, 6(7), pp. 1–11. doi: 10.1371/journal.pone.0022163.

Owen, M. R., Doran, E. and Halestrap, A. P. (2000) 'Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain', *Biochem J*, 614, pp. 607–614.

Ploeg, M., Aben, K. K. and Kiemeney, L. A. (2009) 'The present and future burden of urinary bladder cancer in the world', *World J Urol*, 27, pp. 289–293. doi: 10.1007/s00345-009-0383-3.

Purnomo, B. B. (2003) *Dasar-Dasar Urologi*. Jakarta: Sagung Seto.

Sobin, L., Gospodarowicz, M. and Wittekind, C. (2009) *TNM Classification of Malignant Tumours*. 7ed edn. Wiley Blackwell.

Stenzl, A. *et al.* (2011) 'Treatment of Muscle-invasive and Metastatic Bladder Cancer : Update of the EAU Guidelines', *European Urology*, 59, pp. 1009–1018. doi: 10.1016/j.eururo.2011.03.023.

Sternberg, C. N. *et al.* (2013) 'ICUD-EAU International Consultation on Bladder Cancer 2012 : Chemotherapy for Urothelial Carcinoma — Neoadjuvant and Adjuvant Settings', 63, pp. 58–66.

Sternberg, C. N., Skoneczna, A. and Castellano, D. (2013) 'Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced / Metastatic Urothelial Tract or Bladder Cancer : A Randomized , Active-Controlled , Phase III Trial (CILAB)', *Oncology*, pp. 208–215. doi: 10.1159/000354085.

Takane, H. (2008) 'Polymorphism in human organic cation transporters and metformin action', *Phargonomics*, 9, pp. 415–422.

Teixeira, S. F. *et al.* (2013) 'Original Article', 39(July), pp. 644–649.

Tzvetkov, M. V *et al.* (2009) 'The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1 , OCT2 , and OCT3 on the Renal Clearance of Metformin', *Clinical Pharmacology & Therapeutics*. Nature Publishing Group, 86(3), pp. 299–306. doi: 10.1038/clpt.2009.92.

Wang, D. and Wu, X. (2015a) 'In vitro and in vivo targeting of bladder carcinoma with metformin in combination with cisplatin', *Oncology letters*. 2015/05/26. D.A.

Spandidos, 10(2), pp. 975–981. doi: 10.3892/ol.2015.3267.

Wang, D. and Wu, X. (2015b) 'In vitro and in vivo targeting of bladder carcinoma with metformin in combination with cisplatin', *Oncology Letters*, (8), pp. 975–981. doi: 10.3892/ol.2015.3267.

Wang, Y., He, S.-J. and Feng, X. (2017) 'Metformin : a review of its potential indications', *Dovepress*, pp. 2421–2429.

Wein, A., Kavoussi, L. and Partin, A. (2016) *Campbel-Walsh Urology*. 11th edn. Philadelphia : Elsevier.

Yafi, F. A. and Kassouf, W. (2009) 'Radical cystectomy is the treatment of choice for invasive bladder cancer', *CUAJ*, 3(5), pp. 409–412.

Zhang, L. *et al.* (2003) 'The Oncogene Phosphatidylinositol 3 ′ -Kinase Catalytic Subunit α Promotes Angiogenesis via Vascular Endothelial Growth Factor in Ovarian Carcinoma', *Cancer Research*, (August).

Zhang, T. *et al.* (2013) 'The Antidiabetic Drug Metformin Inhibits the Proliferation of Bladder Cancer Cells in Vitro and in Vivo', *Int J Mol Sci*, 4, pp. 24603–24618. doi: 10.3390/ijms141224603.

Zhou, M., Xia, L. and Wang, J. (2007) 'Metformin Transport by a Newly Cloned Proton-Stimulated Organic Cation Transporter (Plasma Membrane Monoamine Transporter) Expressed in Human Intestine ABSTRACT ':, *Drug Metabolism and Disposition*, 35(10), pp. 1956–1962. doi: 10.1124/dmd.107.015495.dependent.